Biological characteristics and therapeutic response of intraductal component of breast cancer
乳腺癌导管内成分的生物学特性和治疗反应
基本信息
- 批准号:06671178
- 负责人:
- 金额:$ 1.28万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for General Scientific Research (C)
- 财政年份:1994
- 资助国家:日本
- 起止时间:1994 至 1995
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
[Introduction] Tumor-associated antigens including MUC1, sialyl-Tn have been shown to be expressed in breast cancer. Little is known about biological significance of intraductal carcinoma, however, on the basis of expression of antigens or oncogene products. Intraductal spread of carcinoma (ISC) was defined as a state in which DCIS was extending beyond terminal duct-lobular unit (TDLU) and into large ducts. We have proposed ISC grade based on its extent in duct-lobular system and shown how closely it correlated with carcinoma residue after breast conserving surgery. Also, extent of intraductal carcinoma has been considered to be a prognosic factor for local recurrence after breast conserving therapy. This study was intiated to define any biological features exist in intraductal component of breast carcinoma tissues as carcinoma spreads intraductally.[Materials and Methods] Fourty specimens from breast cancer patients receiving partial mastectomy were subjected to 3-D mapping of the tum … More or along with duct-lobular system. Immunohistochemical analysis using monoclonal antibodies DF3 (anti-MUC1), B72.3 (anti-sialyl-Tn), DO7 (anti-p53), and polyclonal antibody SV2-61 (anti-c-erbB-2) was performed on tissue specimens cut at 5 mum in thickness. The specimens were divided into two groups ; high degree of ISC and low degree of ISC.[Results and Discussion] No enhanced expression of c-erbB-2 or p53 products was found in specimens with high ISC degree. MUC1 and sialyl-Tn were intensified, however, in specimens with high degree of ISC ; MUC1 was expressed in 35% of specimens with high degree vs18%with low degree, and sialyl-Tn was expressed in 25% of specimens with high degree vs 0% with low degree. Furthermore, 55% of specimens with high ISC degree demonstrated either of MUC1 and sialyl-Tn antigens, whereas 18% with low degree showed either of the antigens (P<0.05). Surgical specimens from breast cancer patients were investigated to define the site of origin and intraductal spreading of carcinoma using a computer-assisted 3-D mapping. Some of the specimens were immunohistochemically stained with antibodies which recognize, tumor-associated antigens including MUC1, TAG-72 and AM antigens, and protooncogene products, c-erbB-2 and ras p21.The results suggest that MUC1 and sialyl-Tn antigens are expressed as carcinoma extends intraductally, and that the antigen expression may predict local recurrence after breast conserving therapy. The higher the ISC grade observed, the more progressed phase is considered, as MUC1 and sialy1-Tn antigens are often enhanced in tissue or serum of the patients with advanced breast cancer. Less
[简介]包括MUC1,siAllyl-TN在内的肿瘤相关抗原已显示在乳腺癌中表达。然而,基于抗原或癌基产物的表达,对导管内癌的生物学知识知之甚少。癌(ISC)的导管内扩散被定义为DCIS延伸到末端导管 - 细胞单位(TDLU)并进入大型导管的状态。我们已经根据管道细胞系统的范围提出了ISC等级,并显示了乳腺癌保存手术后与癌居住的密切相关。同样,导管内癌的程度被认为是乳房保存治疗后局部复发的预后因素。这项研究的直觉是为了定义乳腺癌组织内导管成分中存在任何生物学特征,因为癌在球内扩散。[材料和方法]接受部分乳腺癌切除术的乳腺癌患者的四十个标本受到肿胀的3-D映射…更多或与导管细胞系统有关。使用单克隆抗体DF3(抗MUC1),B72.3(抗SiAlyl-TN),DO7(抗p53)和多克隆抗体SV2-61(抗C-ERBB-2)进行免疫组织化学分析。样品分为两组。 ISC的高度和低度。[结果和讨论]在具有较高ISC程度的标本中未发现C-ERBB-2或p53产物的表达增强。然而,在具有高度ISC的标本中,MUC1和siAllyl-TN受到了启发。 MUC1在35%的高度VS18%的标本中表达,低度为18%,而在高度vs 0%(低度)的标本中,siAllyl-TN表示。此外,具有高ISC度的标本中有55%表现出MUC1和siAllyl-TN抗原的表现,而低度的18%显示了任何一种抗原(p <0.05)。研究了乳腺癌患者的手术标本,以使用计算机辅助的3-D映射定义癌的起源部位和导管内扩散。 Some of the specimens were immunohistochemically stained with antibodies which recognize, tumor-associated antigens including MUC1, TAG-72 and AM antigens, and protooncogene products, c-erbB-2 and ras p21.The results suggest that MUC1 and sialyl-Tn antigens are expressed as carcinoma extends intraductally, and that the antigen expression may predict local recurrence after breast保存治疗。观察到的ISC等级越高,考虑到进步阶段越多,因为MUC1和SIALY1-TN抗原在患有晚期乳腺癌患者的组织或血清中通常会增强。较少的
项目成果
期刊论文数量(33)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Ohuchi, N. et al.: "Management of duct carcinoma in situ with nipple discharge." Cancer. 74. 1294-1302 (1994)
Ohuchi, N. 等人:“伴有乳头溢液的原位导管癌的治疗。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
大内憲明、他: "乳管小葉区域切除術(Duct-lobular segmentectomy)" 手術. 49. 1061-1065 (1995)
Noriaki Ouchi 等人:“导管小叶段切除术”手术 49. 1061-1065 (1995)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Ohuchi N,: "Management of duct carcinoma in situ sith nipple discharge:intraductal spreading of carcinoma is unfavorable pathologic factor for breast conserving surgery." Cancer. 74. 1294-1302 (1994)
Ohuchi N,:“导管原位癌乳头溢液的治疗:导管内癌扩散是保乳手术的不利病理因素。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Yaegashi, et al.: "Low incidence of a nucleotide seguence of the neurofibromatosis 2 gene in human breast cancers." Jpn. J. Cancer Res.86. 929-933 (1995)
Yaegashi 等人:“人类乳腺癌中神经纤维瘤病 2 基因的核苷酸序列发生率较低。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Ohuchi N. et al: "Characterization of surface antigens expressed in HMA-1 breast cancer cell line." Surgery Today. 25. 244-250 (1995)
Ohuchi N. 等人:“HMA-1 乳腺癌细胞系中表达的表面抗原的表征。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
OHUCHI Noriaki其他文献
OHUCHI Noriaki的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('OHUCHI Noriaki', 18)}}的其他基金
Development of nano-particles with tumor retention by single molecular DDS imaging
通过单分子 DDS 成像开发具有肿瘤保留作用的纳米颗粒
- 批准号:
20310067 - 财政年份:2008
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Establishment of breast cancer screening system based on individual breast constitution
基于个体乳腺体质的乳腺癌筛查体系的建立
- 批准号:
18591428 - 财政年份:2006
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Magnetic resonance imaging of breast cancer : Correlation between contrast enhancement and tumor angiogenesis
乳腺癌的磁共振成像:对比增强与肿瘤血管生成之间的相关性
- 批准号:
10671092 - 财政年份:1998
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of breast cancer extension using new imaging technology, 3-D MRI
使用新成像技术 3-D MRI 分析乳腺癌扩散
- 批准号:
08671328 - 财政年份:1996
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
3-D analysis of intraductal spreading of breast cancer based on expression of protooncogenes and tumor-associated antigens : Application in breast conserving surgery
基于原癌基因和肿瘤相关抗原表达的乳腺癌导管内扩散的 3-D 分析:在保乳手术中的应用
- 批准号:
04670721 - 财政年份:1992
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
相似海外基金
Real-time molecular-imaging guidance of breast conserving surgery
实时分子影像指导保乳手术
- 批准号:
478297 - 财政年份:2023
- 资助金额:
$ 1.28万 - 项目类别:
Operating Grants
Quantitative OCT-Raman spectral imaging for intra-operative detection of positive margins in breast conserving surgery
定量 OCT-拉曼光谱成像用于保乳手术中阳性切缘的术中检测
- 批准号:
MR/Y008731/1 - 财政年份:2023
- 资助金额:
$ 1.28万 - 项目类别:
Research Grant
Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer
新辅助来那替尼治疗 I-III 期 HER2 突变小叶乳腺癌
- 批准号:
10660734 - 财政年份:2023
- 资助金额:
$ 1.28万 - 项目类别:
Deciphering the Acidic Tumor Environment: A Phase I/IIa Study of Pre-Operative Multiparametric MRI and pHLIP® ICG Intra-Operative Fluorescence Imaging of Primary Breast Cancer
破译酸性肿瘤环境:原发性乳腺癌术前多参数 MRI 和 pHLIP® ICG 术中荧光成像的 I/IIa 期研究
- 批准号:
10586615 - 财政年份:2023
- 资助金额:
$ 1.28万 - 项目类别:
GigaFIBI; rapid, large-format histology-resolution imaging for Intraoperative assessment of breast lumpectomy margins
千兆FIBI;
- 批准号:
10568823 - 财政年份:2023
- 资助金额:
$ 1.28万 - 项目类别: